No Monitoring needed if there are no Storage Conditions on the Outer Packaging?
Recommendation
14-16 May 2025
Vienna / Schwechat, Austria
Two-day training + 1-day Airport tour at Vienna Airport in cooperation with DHL
Register now for ECA's GMP Newsletter
"Is it acceptable that storage conditions are not monitored for medicinal products which do not have any predefined storage conditions on the outer packaging?" This question was the first GDP-related question being published along with an answer in the Q&A Section of EMA's website.
And EMA gives a clear answer: "No".
The justification is based on the Guideline on declaration of storage conditions (CPMP/QWP/609/96 Rev. 2). If a marketing authorisation holder (MAH) does not want to include storage conditions on the labelling, the MAH at least will need to provide stability data for storage conditions at 25°C / 60% relative humidity (RH), or 30°C / 65% RH (long term) and 40°C / 75% RH (accelerated). This stability data is based on the temperature and humidity conditions of climate zone I (temperate) and II (Mediterranean/subtropical) in Europe.
As a consequence, controls should be in place to maintain conditions relevant to these climate zones, if no labelling statement is given. This means that the temperature should be monitored during storage and transport.
Related GMP News
23.04.2025MHRA Class 2 Recall due to Blister Pack Mislabeling
15.04.2025Falsified Medicinal Products: Swissmedic Intensifies Controls on International Trade
15.04.2025EMA's 3-Year Work Plan for GMDP Inspectors Working Group: What's Planned for GDP?
15.04.2025Two GDP Non-Compliance Reports published in March
15.04.2025Visit the DHL Vienna Airport Campus
15.04.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 1